These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 9788488)

  • 1. Tolcapone and neurotoxicity in Parkinson's disease.
    Kuhn W; Woitalla D; Gerlach M; Russ H; Müller T
    Lancet; 1998 Oct; 352(9136):1313-4. PubMed ID: 9788488
    [No Abstract]   [Full Text] [Related]  

  • 2. Vitiligo associated with tolcapone and levodopa in a patient with Parkinson's disease.
    Sabaté M; Bosch A; Pedrós C; Figueras A
    Ann Pharmacother; 1999 Nov; 33(11):1228-9. PubMed ID: 10573327
    [No Abstract]   [Full Text] [Related]  

  • 3. Catechol-O-methyltransferase inhibitors in Parkinson's disease.
    Henry C; Wilson JA
    Lancet; 1998 Jun; 351(9120):1965-6. PubMed ID: 9654299
    [No Abstract]   [Full Text] [Related]  

  • 4. Tolcapone for Parkinson's disease.
    Med Lett Drugs Ther; 1998 Jun; 40(1028):60-1. PubMed ID: 9629124
    [No Abstract]   [Full Text] [Related]  

  • 5. Tolcapone and fulminant hepatitis.
    Assal F; Spahr L; Hadengue A; Rubbia-Brandt L; Burkhard PR
    Lancet; 1998 Sep; 352(9132):958. PubMed ID: 9752821
    [No Abstract]   [Full Text] [Related]  

  • 6. Catechol-O-methyltransferase inhibitors in Parkinson's disease.
    Harper J; Vieira B
    Lancet; 1998 Aug; 352(9127):578. PubMed ID: 9716090
    [No Abstract]   [Full Text] [Related]  

  • 7. Switch-over from tolcapone to entacapone in severe Parkinson's disease patients.
    Onofrj M; Thomas A; Iacono D; Di Iorio A; Bonanni L
    Eur Neurol; 2001; 46(1):11-6. PubMed ID: 11455177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Catechol-O-methyltransferase inhibitors: new options for Parkinson's disease.
    Leicht MJ; Mitchell SD
    S D J Med; 1999 Aug; 52(8):295-7. PubMed ID: 10453205
    [No Abstract]   [Full Text] [Related]  

  • 9. Tolcapone added to levodopa in stable parkinsonian patients: a double-blind placebo-controlled study. Tolcapone in Parkinson's Disease Study Group II (TIPS II).
    Dupont E; Burgunder JM; Findley LJ; Olsson JE; Dorflinger E
    Mov Disord; 1997 Nov; 12(6):928-34. PubMed ID: 9399217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Tolcapone: a different, effective approach to improving dopaminergic treatment in Parkinson's disease].
    Kulisevsky J
    Neurologia; 1998 Feb; 13(2):74-82. PubMed ID: 9578674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolcapone, bromocriptine, and Parkinson's disease. French Tolcapone Study Group.
    Agid Y; Destée A; Durif F; Montastruc JL; Pollak P
    Lancet; 1997 Sep; 350(9079):712-3. PubMed ID: 9291909
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson's disease.
    Lees AJ; Ratziu V; Tolosa E; Oertel WH
    J Neurol Neurosurg Psychiatry; 2007 Sep; 78(9):944-8. PubMed ID: 17098835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolcapone-related liver dysfunction: implications for use in Parkinson's disease therapy.
    Borges N
    Drug Saf; 2003; 26(11):743-7. PubMed ID: 12908845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-life evaluations of compliance with mandatory drug safety monitoring exemplified with tolcapone in Parkinson's disease.
    Unger MM; Reese JP; Oertel WH; Eggert KM
    Eur Neurol; 2008; 60(3):122-6. PubMed ID: 18628629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of tolcapone on the haemodynamic effects and tolerability of desipramine.
    Jorga KM; Fotteler B; Modi M; Rabbia M
    Eur Neurol; 2000; 44(2):94-103. PubMed ID: 10965161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Akathisia secondary to tolcapone. Report of a case].
    Colorado-Ochoa H
    Gac Med Mex; 2000; 136(5):505-9. PubMed ID: 11080934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolcapone: new drug. In Parkinson's disease: unacceptable risk of severe hepatitis.
    Prescrire Int; 2006 Apr; 15(82):54-7. PubMed ID: 16604736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of Parkinson's disease with COMT inhibitors: tolcapone].
    Avila A; Kulisevsky J
    Neurologia; 1998; 13 Suppl 1():66-71. PubMed ID: 9859687
    [No Abstract]   [Full Text] [Related]  

  • 19. A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients. Tolcapone De Novo Study Group.
    Hauser RA; Molho E; Shale H; Pedder S; Dorflinger EE
    Mov Disord; 1998 Jul; 13(4):643-7. PubMed ID: 9686768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease.
    Kaakkola S
    Int Rev Neurobiol; 2010; 95():207-25. PubMed ID: 21095464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.